Is There a Tirzepatide Pill? What Exists in 2026

Is There a Tirzepatide Pill? What the FDA Has Approved

No. Two tirzepatide products carry FDA approval, and both are injections. Mounjaro was approved in 2022 for type 2 diabetes. Zepbound followed in November 2023 for chronic weight management in adults with obesity, or with overweight plus a weight-related condition. Each is a single-patient pen, injected under the skin once a week, and neither has an oral counterpart on the market.

That gap does not look like a backlog. The molecule itself does not survive the trip through a stomach in an ordinary tablet, which is a different kind of problem from a drug that simply has not been reformulated yet. The next section explains what happens to it.

The search results are muddy for a specific reason. Eli Lilly, the company behind tirzepatide, also makes a GLP-1 pill that won FDA approval in 2026. It is easy to read those two facts together and conclude Lilly put tirzepatide in a tablet. That is not what happened, and the difference matters clinically. For the approval history in detail, see is tirzepatide FDA approved.

Why Tirzepatide Does Not Exist as a Pill

Tirzepatide is a peptide: a chain of amino acids, engineered to activate two receptors at once, GLP-1 and GIP. Peptides are what the digestive system is built to take apart. Stomach acid starts the job and enzymes called peptidases finish it, cutting the chain into fragments long before it can cross the intestinal wall intact. Swallow a peptide drug in an ordinary tablet and you have mostly eaten protein.

Injecting it sidesteps the problem entirely. A subcutaneous dose enters the tissue under the skin and reaches the bloodstream without passing through the gut, which is why every approved tirzepatide product is a pen.

Digestive enzymes cut peptide drugs apart, while small-molecule drugs are built to survive the stomach and be absorbed.

Semaglutide, the other well-known GLP-1 peptide, shows how much engineering the workaround takes. Its oral tablets are co-formulated with salcaprozate sodium (SNAC), an absorption enhancer, and still come with an unusually strict routine. The current prescribing information for oral semaglutide instructs patients to take the tablet on an empty stomach in the morning with no more than 4 ounces of plain water and no other liquid, swallow it whole, and wait at least 30 minutes before eating, drinking, or taking other oral medications. Even with the enhancer and that routine, the label puts absolute oral bioavailability at roughly 0.4% to 2% [7]. No equivalent enhanced-oral tirzepatide formulation has cleared trials and reached approval.

None of this makes the injectable form second best. It is the form the trial evidence covers, including SURMOUNT-1, the 72-week study behind Zepbound's weight-management approval. See the tirzepatide dosing guide for how the weekly schedule is built.

Orforglipron (Foundayo): The Oral GLP-1 Pill That Is Not Tirzepatide

The FDA approved orforglipron, sold as Foundayo, on April 1, 2026 [6], for adults with obesity, or overweight with a weight-related medical problem, alongside a reduced-calorie diet and more physical activity. It is a once-daily tablet from Eli Lilly, and it is worth being precise about what it is.

A different molecule, not a reformulation

Foundayo is not tirzepatide reformulated as a pill. Orforglipron is an oral small-molecule GLP-1 receptor agonist, as the New England Journal of Medicine describes it. Small molecules are compact, non-peptide compounds, a class that turns up as tablets far more often than peptides do. Tirzepatide is a peptide that activates two receptors, GLP-1 and GIP. Orforglipron acts at the GLP-1 receptor.

Two different molecules from the same manufacturer, often confused because both are GLP-1 medicines from Eli Lilly.

Foundayo dosing and how it is taken

Foundayo comes in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg oral tablets, taken by mouth once each day with or without food, swallowed whole, and never more than one tablet per day. Those strengths are not a menu to choose from. The label sets a fixed escalation: start at 0.8 mg once daily, move to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 days more. Any further step up to 9 mg, 14.5 mg, or 17.2 mg also requires at least 30 days at the current dose and is based on how the patient responds and tolerates it. The maximum is 17.2 mg once daily [3].

That "with or without food" line is a real practical difference from oral semaglutide, which carries the empty-stomach instruction and the 30-minute wait described earlier. Foundayo has no such timing rule in its dosing information.

A walkthrough of what orforglipron (Foundayo) is and why it is a distinct drug rather than an oral version of Zepbound.

What About Compounded "Oral Tirzepatide"?

Search the phrase and you will find products for sale: dissolving tablets, sublingual drops, troches, marketed by telehealth companies and compounding pharmacies. These are real businesses with real checkout pages. They are not counterfeit operations run out of nowhere, and they are also not FDA-approved.

The difference comes down to one thing. FDA approval means an agency reviewed manufacturing, purity, dosing, and clinical evidence for that specific formulation. Compounded oral tirzepatide has not been through that review, so nothing in the public record establishes how much tirzepatide, if any, a given product delivers into the bloodstream.

The pharmacology splits by route. For anything meant to be swallowed, the peptide-degradation problem described above applies exactly as it does to any other swallowed peptide. Sublingual drops and troches are a different case: they are designed to absorb through the lining of the mouth precisely to avoid stomach acid and gut peptidases. That is the intent behind the route. Whether it works for a peptide this size is a separate question, and no published data establish how much tirzepatide reaches the bloodstream that way.

None of that tells you a specific seller is acting in bad faith. It tells you the evidence a prescription drug normally carries is absent, and that anyone considering one is accepting an unquantified dose. If you are weighing compounded tirzepatide in any form, read compounded tirzepatide first and raise it with a clinician.

If You Want an Oral GLP-1 Today

Wanting to skip the needle is reasonable, and there are approved routes to it. They just do not involve tirzepatide.

Orforglipron (Foundayo) is the newer option: a once-daily tablet approved in April 2026 for adults with obesity, or overweight with a weight-related medical problem, taken with or without food.

Oral semaglutide is the older one, sold under two brand names split by indication. The Ozempic pill is approved for type 2 diabetes [8], and the Wegovy pill is approved for weight management [9]. Both labels carry the same empty-stomach routine and the same 30-minute wait before food, other drinks, or other oral medicines [7][11].

Neither is tirzepatide, and neither should be assumed to behave like tirzepatide. If you are currently on Mounjaro or Zepbound and want to move to a pill, that is a prescriber conversation about switching drugs, not a change in format. The comparison in tirzepatide vs semaglutide is a useful starting point for that discussion.

Tirzepatide Pill vs. the Injectable Pens (Mounjaro and Zepbound)

There is no head-to-head comparison to make here, because one side of it does not exist. Every efficacy figure, side-effect rate, and dosing schedule published for tirzepatide comes from the injectable form. There is no approved oral version to compare against, so any claim that oral tirzepatide works better, worse, or the same as the injection has no trial behind it.

What the pens actually involve: a once-weekly subcutaneous injection, doses running from 2.5 mg up to 15 mg, and a titration that usually steps up every four weeks. Tirzepatide's half-life of about 5 days is what makes weekly dosing workable, and it takes roughly 4 to 5 weeks at a given dose for levels to plateau. The most commonly reported side effects are nausea, diarrhea, constipation, and vomiting, mostly mild to moderate and dose-dependent.

For the mechanism behind the dual-receptor design, see what is tirzepatide.

Will a Tirzepatide Pill Ever Exist?

Honest answer: nobody writing this can tell you, and be wary of anyone who claims otherwise. No study in the ClinicalTrials.gov registry lists an oral tirzepatide formulation as an intervention; searches pairing tirzepatide with "oral" return studies using oral comparator drugs, not oral tirzepatide [10]. No publicly announced program exists either. That is a statement about what is on the public record today, not a prediction about laboratory work nobody has disclosed. Filings under review are confidential, so nobody outside a sponsor and the agency can rule one out.

What is fair to say is that the industry's oral momentum has gone in a different direction. Orforglipron reached approval as a small molecule built for oral delivery from the outset, rather than as a peptide retrofitted into a tablet. That is a design choice about how to solve the swallowing problem, and it does not require tirzepatide to be reformulated at all.

If you are planning treatment now, build around what is approved. If tirzepatide is the right drug for you, that means the weekly pen. If a pill is the priority, that means a different molecule and a different conversation with your prescriber.